Keywords
serotonin, MDD, major depressive disorder, serotonin receptor, 5-HT1A, 5-HT1B, 5-HTT, selective serotonin reuptake inhibitors, antidepressant,
Introduction
The serotonin hypothesis of depression has dominated the field of depression for over four decades1. This theory is centered on the idea that reduced serotonin signaling is a risk factor in the etiology and/or pathophysiology of major depressive disorder (MDD)2. However, the most robust body of evidence for the role of serotonin in depression is the efficacy of increasing extracellular serotonin for the treatment of depression. The discovery that the efficacy of tricyclic antidepressants (TCAs) and monoamine oxidase inhibitor (MAOI) antidepressants was largely due to their serotonergic actions, which prompted the use of serotonin selective reuptake inhibitors (SSRIs), the first among them fluoxetine, to treat depression3–6. These drugs act at the serotonin transporter (5-HTT, also known as SERT) and cause increases in extracellular serotonin, which is the purported mechanism of action6–8. Many subsequent drugs inhibiting serotonin reuptake have shown behavioral efficacy as antidepressant drugs, suggesting that increasing synaptic serotonin levels may lead to the treatment of depression6,9.
Despite the relative success in treating depression by increasing extracellular serotonin, there is a lack of strong evidence supporting a direct correlation between low serotonin signaling and depression. While some studies report an association between levels of platelet serotonin and depression, this has not been a consistent finding in large sample sets, and it is also unclear how platelet levels are related to brain levels of serotonin10,11. Additionally, few studies report direct correlations between cerebrospinal fluid 5-hydroxyindoleacetic acid (5-HIAA), a serotonin metabolite, and depression12,13. Low levels of tryptophan have been consistently linked to depression; however, these effects could be independent of serotonin14,15. The lack of consistent clear-cut abnormalities in global measures of serotonin signaling isn’t surprising if one considers the complexity of the receptors at which serotonin binds, the intricate neuroanatomical circuitry of the serotonin system, and the developmental role serotonin plays as a neurotrophic factor16–18. Many recent studies have focused on understanding the mechanisms through which serotonin affects depression by studying the impact of 5-HTT and the 15 known receptors through gene-association studies, human brain imaging, and pharmacological and genetic mouse models19.
The success in treating depression by targeting the transporter with SSRIs prompted investigations into whether variability in 5-HTT expression levels could be involved in the etiology of depression. A highly cited study showed that there is an association between a polymorphism in the serotonin transporter (5-HTTLPR) and susceptibility to developing depression20. This and other studies have shown that the short “s” allele, which results in lower levels of 5-HTT expression (at least in vitro) and therefore increased extracellular 5-HT, is associated with a higher risk of depression when combined with stressful life events21,22. This discovery would be unexpected if developmental considerations were not considered. Although inhibiting the function of the transporter during adulthood decreases depressive symptoms as in the case of SSRIs, reduced expression of 5-HTT during development may increase depressive behavior in adulthood. A human functional magnetic resonance imaging (fMRI) study supports this, showing that short allele carriers show morphological and functional alterations in limbic circuits23. Additionally, mice lacking 5-HTT throughout life display increased depressive-like behaviors, and pharmacological blockade of 5-HTT in mice exclusively during early postnatal development resulted in increased adult depressive behavior24. These results highlight the differences in developmental versus adult effects of altered serotonin neurotransmission on depression.
In addition to the serotonin transporter, the majority of the 15 serotonin receptors have been implicated in the modulation of depression, depressive-like behaviors, or the response to anti-depressant treatment19. There are numerous pre-clinical studies which have investigated the role of serotonin receptors using pharmacological manipulations and genetic knockout (KO) models in rodents (Table 1). Given the breadth of this literature, this review will focus on two receptors that are among the most extensively studied for their role in modulating depression, the 5-HT1A and 5-HT1B receptor subtypes. In addition, attention will be paid to population-dependent and development-dependent effects of serotonin signaling at these receptors and will draw from both rodent and human studies.
Table 1. Preclinical evidence supporting the role for serotonin receptors in depression.
Receptor | PubMed Hits* | Pharmacological studies on depression | Genetic effects on depression | Other behavioral phenotypes |
---|
5-HT2A | 588 | Antagonists have antidepressant-like effects and potentiate the effects of SSRIs133,134 | No known effect of 5-HT2A KO on depressive-like behavior135 | Agonists are hallucinogenic; antagonists are antipsychotic and anxiolytic; KO mouse has reduced anxiety-like behavior135–137 |
5-HT2B | 52 | Agonists have antidepressant-like effects138 | Required for behavioral effects of SSRIs138,139 | KO mouse shows increased impulsivity140 |
5-HT2C | 282 | Antagonists have antidepressant-like effects; agonists have pro-depressive effects141,142 | No known effect of 5-HT2C KO on depressive-like behavior | Antagonists have anxiolytic effects; agonists decrease impulsivity and motivation for drug and food consumption; KO mouse has reduced anxiety-like behavior143–145 |
5-HT3A | 252 | Antagonist has antidepressant-like effects146 | 5-HT3 required for exercise-induced antidepressant effects; KO has antidepressant-like phenotype147,148 | Antagonists are anxiolytic149 |
5-HT4 | 81 | Agonists have rapid antidepressant-like effects150,151 | KO has attenuated responses to stress152 | Agonists are anxiolytic; agonists improve cognitive performance and reduce feeding151,153 |
5-HT5A | 5 | Unknown | Unknown | KO mice display increased exploratory behavior154 |
5-HT6 | 62 | Agonists produce antidepressant-like effects and antagonists block the effects of SSRIs155,156 | Unknown | Antagonists enhance cognitive performance; blockade of signaling is anxiogenic157,158 |
5-HT7 | 137 | Antagonists have antidepressant-like effects159 | KOs have an antidepressant-like phenotype159 | Antagonists have pro-cognitive effects160 |
The 5-HT1A and 5-HT1B receptors are both inhibitory Gi/o-coupled seven transmembrane receptors that are located throughout the brain25–27. A major difference between these two receptors is their subcellular distribution28. 5-HT1A receptors are somatodendritic, while 5-HT1B receptors are located on axon terminals27,29. This difference is also reflected in their mechanisms of inhibitory action (Figure 1). Activation of either receptor causes decreased neurotransmitter release; however, 5-HT1A receptor activation causes hyperpolarization, leading to decreased firing, while 5-HT1B receptors inhibit voltage-gated calcium channels in the presynaptic terminal30–32. Another mechanism for 5-HT1B receptor-mediated inhibition is via effects on 5-HTT, and activation of the 5-HT1B receptor increases serotonin reuptake33,34.
Figure 1. Schematic illustrating the inhibitory effects of serotonin (5-hydroxytryptamine, 5-HT) 1A (5-HT1A) (red) and 5-HT1B (blue) receptors on the normal firing and neurotransmitter release of a neuron (top).
Activation of 5-HT1A receptors results in decreased firing (middle), while activation of 5-HT1B receptors causes decreased neurotransmitter release through actions in the presynaptic terminal (bottom).
Both 5-HT1A and 5-HT1B receptors act as autoreceptors located on serotonin neurons and also have heteroreceptor populations located on non-serotonin receptors (Figure 2). Although the mRNA in the raphe (corresponding to autoreceptors) is comparable between the two receptors, their heteroreceptors have distinct patterns of expression35. 5-HT1A receptors are enriched in the hippocampus and cortex, while 5-HT1B receptors are highly expressed in the basal ganglia36,37. These differences in mechanism of action and localization may play a role in the different functional effects of these receptors.
Figure 2. Diagram summarizing the roles of autoreceptor and heteroreceptor populations of serotonin (5-hydroxytryptamine, 5-HT) 1A (5-HT1A) and 5-HT1B receptors on behavior during development and adulthood.
5-HTT, serotonin transporter.
While this review focuses on the contribution of 5-HT1A and 5-HT1B receptors in depression and depressive-like behaviors, these receptors also modulate other psychiatric-relevant phenotypes. For example, alterations in 5-HT1A receptor expression influence anxiety behavior, and 5-HT1B receptor signaling affects reward- and impulsivity-related phenotypes. These receptor-based differences in serotonergic regulation of emotional behavior, which segment into endophenotypes, could contribute to the heterogeneity of symptoms found in MDD38. Understanding the neural circuits that subserve these receptor-based and endophenotype-based differences can help clarify the often confusing and sometimes contradictory findings from various preclinical approaches. From a behavioral perspective, these phenotypes can be segmented through formal unsupervised factor analyses to better divide depressive behaviors into meaningful endophenotypes. Then predictors of the different endophenotypes could be tested by including genetic or pharmacological manipulations.
5-HT1A and depression
Of the 15 known serotonin receptors, the 5-HT1A receptor is the most studied for its role in depression39. Quantification of 5-HT1A receptor levels in humans from post mortem and positron emission tomography (PET) imaging studies reveals an increased level of 5-HT1A receptors in patients diagnosed with MDD40–42. Gene association studies have linked a polymorphism in the 5-HT1A regulatory region (rs6295; G-1019C) with receptor levels in the brain and also to increased risk for depression43–47. The GG genotype at this single nucleotide polymorphism (SNP) is associated with altered levels of 5-HT1A receptor expression and reduced responsiveness to antidepressant treatment43,48. Additionally, clinical studies have revealed antidepressant effects of buspirone and other 5-HT1A receptor agonists49,50.
Rodent models have also shown that 5-HT1A receptor agonists, such as 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), can have acute antidepressant-like effects51–53. These effects are blocked by 5-HT1A receptor antagonists, suggesting that the antidepressant-like response is specific to 5-HT1A receptor signaling54. 5-HT1A heteroreceptors, expressed throughout the limbic system, are the likely site of action for these acute 5-HT1A receptor-mediated effects50,55. On the other hand, 5-HT1A autoreceptors work in opposition to the heteroreceptors, leading to pro-depressive effects. Specifically, activation results in hyperpolarization and reduced firing of raphe neurons, leading to diminished serotonin release in projection regions56. Therefore, stimulation of 5-HT1A autoreceptors from increased extracellular serotonin following SSRI treatment is thought to oppose SSRI actions by downregulating serotonin neuron activity57. Over the first few weeks of treatment, these receptors desensitize, which may underlie the delayed behavioral efficacy of SSRIs58. Therefore, blocking 5-HT1A autoreceptor activation has been introduced as an adjunctive therapy to SSRIs. 5-HT1A receptor partial agonists such as pindolol, and more recently vilazodone, have been shown to be an effective adjunctive therapy to SSRIs in clinical studies59–62. The development of new agonists that preferentially target subpopulations of 5-HT1A receptors, for example autoreceptors versus heteroreceptors, potentially through biased agonism, may be useful tools for the treatment of MDD63.
Differences in receptor levels have also been modeled in mice by using genetic loss-of-function models and have allowed causal links between receptor expression levels and depressive-like behavior. 5-HT1A receptor KO mice have an anti-depressive phenotype64,65. Tissue-specific KOs have been especially valuable for the dissection of this phenotype and have allowed investigations into the distinct roles of different populations of receptors66. The absence of heteroreceptors results in increased depressive-like behavior- as measured in the forced swim test. This mouse model also allowed for temporal control of receptor expression, which revealed a developmental sensitive period for the effect of heteroreceptors on depressive-like behavior. Specifically, knockdown of 5-HT1A heteroreceptors in adulthood was not sufficient to produce the depressive-like behavior. On the other hand, reduction of autoreceptors in adulthood increased mobility in the forced swim test, suggesting an “anti-depressed” phenotype.
Preclinical studies have also confirmed a causal role for alterations in 5-HT1A receptor expression in antidepressant efficacy. 5-HT1A receptor KO mice do not show a behavioral response to fluoxetine67. As expected from the pharmacology work, this effect is not mediated by autoreceptors, since reduced expression of 5-HT1A autoreceptors actually increases the speed and efficacy of SSRI response, requiring only 8 days of fluoxetine treatment to show a behavioral antidepressant-like response68. Recent data show that 5-HT1A heteroreceptors are critical for an effective behavioral response to an SSRI in mice69. Genetic or viral deletion of 5-HT1A receptors specifically in the dentate gyrus of the hippocampus reduced the behavioral response to fluoxetine. Furthermore, expression of 5-HT1A receptors only in the dentate gyrus was sufficient for normal antidepressant-like responses. These results importantly demonstrate a mechanism for 5-HT1A-mediated antidepressant effects localized in the mature granule cells of the dentate gyrus.
5-HT1A and other psychiatric-relevant phenotypes
Anxiety behavior is also modulated strongly by the 5-HT1A receptor, and, among depressed patients, almost half have a comorbid anxiety disorder70. In preclinical studies, 5-HT1A receptor agonists have anxiolytic effects, and 5-HT1A receptor KO mice display increased anxiety-like behavior64,65,71,72. The effect has a developmental sensitive period, since early developmental but not adult rescue of the receptor was sufficient to restore the normal phenotype in the KO73. Consistent with this, early postnatal blockade of 5-HT1A receptors, through genetic or pharmacological methods, also leads to increased anxiety74,75. Recent work has shown that the sensitive period is peri-pubertal, and tissue-specific KO mice point to a role for autoreceptors during this period of development66,76,77.
Other psychiatric disorders have also been linked to the 5-HT1A receptor, including bipolar disorder and post-traumatic stress disorder78,79. Additionally, the SNP rs6295 found in the premotor region that is associated with risk for depression is also linked with psychiatric hospitalization, a history of substance abuse, and prior suicide attempts43. Consistent with the studies in depression, the G allele is associated with reduced expression of the 5-HT1A receptor in the prefrontal cortex and an increased risk for psychiatric outcomes. Interestingly, the effects on receptor expression were also seen in the brain during early human embryonic development, suggesting its potential importance in mediating developmental contributions to adult depression. Finally, there were associations with childhood maltreatment with trends towards significant genotype by environment interactions40.
5-HT1B and depression
While the 5-HT1B receptor is best known for its role in regulating aggressive and impulsive behavior, it also plays an important role in modulating depression. Activation of the 5-HT1B receptor decreases serotonin levels in the brain through effects on release, synthesis, and reuptake33,80,81. In humans, reduced 5-HT1B receptor function is associated with MDD82. Additionally, patients with MDD are less responsive to 5-HT1B receptor agonists, suggesting reduced expression or desensitization83,84. This is consistent with clinical studies showing that 5-HT1B receptor agonists produce antidepressant effects in humans85–87. This has also been shown in mice, with specific agonists resulting in antidepressant-like behavior88,89. However, genetic KO of the receptor also results in antidepressant-like behavior, suggesting that this is possibly caused by compensatory effects90–94.
Both autoreceptor and heteroreceptor populations of 5-HT1B receptors have been implicated in depressive-like behaviors using rodent models. However, since 5-HT1B receptors are located on presynaptic terminals, heteroreceptors and autoreceptors have overlapping localization95. This rules out brain imaging and pharmacological manipulations in preclinical models as tools to differentiate the role of the two populations of receptors. Therefore, it has been only the recent availability of a tissue-specific genetic mouse model that has allowed the dissection of the role of 5-HT1B receptors in the regulation of behavior96.
Our recent studies show that selective ablation of 5-HT1B autoreceptors results in decreased depressive-like behaviors in mice97. These mice also show increased elevations in serotonin levels compared to controls following SSRI administration, suggesting a potential mechanism of action for the behavioral effects. Specifically, removing the terminal auto-inhibition may result in increased serotonin in projection regions that are relevant to depressive behavior. Furthermore, we also showed that the impact of 5-HT1B autoreceptors on behavior was not due to developmental expression, since the phenotype was not recapitulated in a mouse with developmental knockdown. These data are consistent with other evidence suggesting a pro-depressive role for the activation of 5-HT1B autoreceptors98,99. For example, 5-HT1B mRNA is elevated in the raphe of rats following stress and in models of depression such as learned helplessness, and viral overexpression of 5-HT1B receptors in the raphe results in depressive-like behavior following stress100. In rats, reductions in 5-HT1B receptor mRNA in the raphe are seen following SSRI treatment in post mortem brains101,102. This effect isn’t seen in other brain regions such as the cortex, hippocampus, or striatum, suggesting that this effect is specific to autoreceptors. Additionally, another study showed that 5-HT1B autoreceptors may desensitize following SSRI treatment, similar to 5-HT1A autoreceptors103. Finally, a recent PET study in humans reported that following effective cognitive behavioral therapy for depression, 5-HT1B receptor binding was reduced in the brainstem104.
There is evidence which suggests an opposing role for 5-HT1B heteroreceptors in depressive behaviors. Activation of 5-HT1B heteroreceptors in a rodent serotonin depletion model (to remove the contribution of autoreceptors) results in an antidepressant-like effect105. Additionally, reduced expression of 5-HT1B heteroreceptors in the ventral striatum is associated with depression in humans82. Finally, 5-HT1B receptors located in the ventral striatum have been suggested to interact with p11 (a 5-HT1B receptor-binding protein) to affect depression-related behaviors106,107.
5-HT1B and other psychiatric-related phenotypes
Reward dysfunction is a major symptom of MDD which is mediated, in part, by altered signaling in the mesolimbic reward system108–112. 5-HT1B receptors have been implicated in the neural basis of dysregulated reward sensitivity in a number of human studies and preclinical models113–116, and both 5-HT1B receptor protein and mRNA are located within the mesolimbic pathway in the nucleus accumbens (NAc) and ventral tegmental area (VTA)95. Additionally, activation of 5-HT1B receptors in the VTA increases dopamine levels in the NAc, potentially via effects on GABAergic signaling in the VTA117.
Many studies linking the receptor to functional deficits in reward processing have focused on addiction. Polymorphisms in the 5-HT1B receptor gene have also been associated with drug and alcohol abuse118–120. Additionally, a PET imaging study revealed increased 5-HT1B receptor binding in pathological gamblers, who have known deficits in reward sensitivity, and gambling disorder is highly comorbid with depression and alcohol and substance use disorders116,121. Another PET imaging study shows that there is reduced 5-HT1B receptor binding in cocaine-dependent participants compared to in healthy controls122. In preclinical models, 5-HT1B receptor KO mice are more motivated to self-administer cocaine123. Consistent with this, 5-HT1B receptor agonists attenuate the motivation for cocaine but paradoxically increase the rewarding effects of cocaine124. These effects are mediated by 5-HT1B receptor expression on medium spiny neurons in the NAc, likely through their projections to the VTA125,126. Additionally, 5-HT1B receptors are required for the rewarding properties of social interaction, supporting an impact on general reward systems114.
5-HT1B receptors are also implicated in impulsive aggression. In humans, polymorphisms in the gene encoding 5-HT1B receptors have been associated with aggression, suicide, and disorders that include impulsivity as a core phenotype, including attention deficit hyperactivity disorder and substance use disorder115,120,127. In mice, 5-HT1B receptor KOs are highly aggressive in tests of male and female aggression and also display increased impulsivity128–130. Additionally, 5-HT1B receptor agonists are known as “serenics” because they decrease aggression131. While the aggressive and impulsive phenotype was originally thought to be modulated by the same underlying circuits, our recent work shows that distinct populations of 5-HT1B receptors modulate aggression and impulsivity96. Furthermore, developmental expression of the 5-HT1B receptor influences aggression, while adult expression modulates impulsive behavior.
Conclusion
There is a considerable body of research that implicates serotonin in the modulation of depression and depression-related behaviors. The preclinical work delineating the effects of signaling through the 5-HT1A and 5-HT1B receptors has been made possible because of careful pharmacological studies as well as the development of transgenic mouse models that have allowed for tissue-specific and inducible knockdown. These studies have highlighted the complexity of serotonin receptors, showing that their role varies through the lifespan and by cell-type population. Additionally, the availability of specific radioligands for PET imaging of these receptors has allowed for the translation of findings from preclinical work to humans. The large number of studies concerning the role of these receptors is partially due to the fact that the 5-HT1 receptor subtypes were some of the first discovered, and it may be only a matter of time before the roles of more newly discovered receptors are clarified17.
Despite the amassing of evidence of serotonin receptor-specific involvement in depression, the primary pharmaceutical treatment strategy for depression remains the inhibition of serotonin reuptake. The lack of new treatment options is surprising given the need for them, since current SSRI treatments are ineffective in one-third of patients132. Additionally, the majority of patients, as seen in the STAR*D study, don’t respond to administration of the first SSRI treatment, requiring multi-step treatment plans that take months132. Furthermore, the considerable differences in treatment outcome also emphasize the heterogeneity of the depressed patient population. A better understanding of receptor signaling and neural circuit mechanisms by which serotonin affects depression may inform the development of novel, more targeted drugs that influence specific receptors, signaling cascades, or time periods. Also, personalized treatment plans could be developed based on symptoms, biomarkers, or pathophysiological presentation.
Competing interests
The authors declare that they have no competing interests.
Grant information
Support for René Hen was provided by Hope for Depression Research Foundation (RGA 13-003), NIH R37MH068542, and R01MH083862. Funding for Katherine Nautiyal was provided by NIH K99 MH106731 and a NARSAD Young Investigator Award.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Faculty Opinions recommendedReferences
- 1.
Coppen A:
The biochemistry of affective disorders.
Br J Psychiatry.
1967; 113(504): 1237–64. PubMed Abstract
| Publisher Full Text
- 2.
Albert PR, Benkelfat C:
The neurobiology of depression--revisiting the serotonin hypothesis. II. Genetic, epigenetic and clinical studies.
Philos Trans R Soc Lond B Biol Sci.
2013; 368(1615): 20120535. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 3.
De Montigny C:
Enhancement of the 5-HT neurotransmission by antidepressant treatments.
J Physiol (Paris).
1981; 77(2–3): 455–61. PubMed Abstract
- 4.
AZIMA H, VISPO RH:
Imipramine; a potent new anti-depressant compound.
Am J Psychiatry.
1958; 115(3): 245–6. PubMed Abstract
| Publisher Full Text
- 5.
Messing RB, Phebus L, Fisher LA, et al.:
Analgesic effect of fluoxetine hydrochloride (Lilly 110140), a specific inhibitor of serotonin uptake.
Psychopharmacol Commun.
1975; 1(5): 511–21. PubMed Abstract
- 6.
de Montigny C, Blier P:
Effects of antidepressant treatments on 5-HT neurotransmission: electrophysiological and clinical studies.
Adv Biochem Psychopharmacol.
1984; 39: 223–39. PubMed Abstract
- 7.
Lemberger L, Rowe H, Carmichael R, et al.:
Pharmacologic effects in man of a specific serotonin-reuptake inhibitor.
Science.
1978; 199(4327): 436–7. PubMed Abstract
| Publisher Full Text
- 8.
Nackenoff AG, Moussa-Tooks AB, McMeekin AM, et al.:
Essential Contributions of Serotonin Transporter Inhibition to the Acute and Chronic Actions of Fluoxetine and Citalopram in the SERT Met172 Mouse.
Neuropsychopharmacology.
2016; 41(7): 1733–41. PubMed Abstract
| Publisher Full Text
| Free Full Text
| Faculty Opinions Recommendation
- 9.
Asberg M, Mårtensson B:
Serotonin selective antidepressant drugs: past, present, future.
Clin Neuropharmacol.
1993; 16 Suppl 3: S32–44. PubMed Abstract
- 10.
Mann JJ, McBride PA, Anderson GM, et al.:
Platelet and whole blood serotonin content in depressed inpatients: correlations with acute and life-time psychopathology.
Biol Psychiatry.
1992; 32(3): 243–57. PubMed Abstract
| Publisher Full Text
- 11.
Coppen A, Turner P, Rowsell AR, et al.:
5-Hydroxytryptamine (5-HT) in the whole-blood of patients with depressive illness.
Postgrad Med J.
1976; 52(605): 156–8. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 12.
van Praag HM, de Haan S:
Central serotonin metabolism and frequency of depression.
Psychiatry Res.
1979; 1(3): 219–24. PubMed Abstract
| Publisher Full Text
- 13.
Asberg M, Bertilsson L, Mårtensson B, et al.:
CSF monoamine metabolites in melancholia.
Acta Psychiatr Scand.
1984; 69(3): 201–19. PubMed Abstract
| Publisher Full Text
- 14.
Karege F, Widmer J, Bovier P, et al.:
Platelet serotonin and plasma tryptophan in depressed patients: effect of drug treatment and clinical outcome.
Neuropsychopharmacology.
1994; 10(3): 207–14. PubMed Abstract
| Publisher Full Text
- 15.
Ogawa S, Fujii T, Koga N, et al.:
Plasma L-tryptophan concentration in major depressive disorder: new data and meta-analysis.
J Clin Psychiatry.
2014; 75(9): e906–15. PubMed Abstract
| Publisher Full Text
- 16.
Gaspar P, Cases O, Maroteaux L:
The developmental role of serotonin: news from mouse molecular genetics.
Nat Rev Neurosci.
2003; 4(12): 1002–12. PubMed Abstract
| Publisher Full Text
- 17.
Barnes NM, Sharp T:
A review of central 5-HT receptors and their function.
Neuropharmacology.
1999; 38(8): 1083–152. PubMed Abstract
| Publisher Full Text
- 18.
Bang SJ, Jensen P, Dymecki SM, et al.:
Projections and interconnections of genetically defined serotonin neurons in mice.
Eur J Neurosci.
2012; 35(1): 85–96. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 19.
Carr GV, Lucki I:
The role of serotonin receptor subtypes in treating depression: a review of animal studies.
Psychopharmacology (Berl).
2011; 213(2–3): 265–87. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 20.
Caspi A, Sugden K, Moffitt TE, et al.:
Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene.
Science.
2003; 301(5631): 386–9. PubMed Abstract
| Publisher Full Text
| Faculty Opinions Recommendation
- 21.
Karg K, Burmeister M, Shedden K, et al.:
The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation.
Arch Gen Psychiatry.
2011; 68(5): 444–54. PubMed Abstract
| Publisher Full Text
| Free Full Text
| Faculty Opinions Recommendation
- 22.
Risch N, Herrell R, Lehner T, et al.:
Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis.
JAMA.
2009; 301(23): 2462–71. PubMed Abstract
| Publisher Full Text
| Free Full Text
| Faculty Opinions Recommendation
- 23.
Pezawas L, Meyer-Lindenberg A, Drabant EM, et al.:
5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression.
Nat Neurosci.
2005; 8(6): 828–34. PubMed Abstract
| Publisher Full Text
| Faculty Opinions Recommendation
- 24.
Ansorge MS, Zhou M, Lira A, et al.:
Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice.
Science.
2004; 306(5697): 879–81. PubMed Abstract
| Publisher Full Text
| Faculty Opinions Recommendation
- 25.
Albert PR, Robillard L:
G protein specificity: traffic direction required.
Cell Signal.
2002; 14(5): 407–18. PubMed Abstract
| Publisher Full Text
- 26.
Laporte AM, Lima L, Gozlan H, et al.:
Selective in vivo labelling of brain 5-HT1A receptors by [3H]WAY 100635 in the mouse.
Eur J Pharmacol.
1994; 271(2–3): 505–14. PubMed Abstract
| Publisher Full Text
- 27.
Boschert U, Amara DA, Segu L, et al.:
The mouse 5-hydroxytryptamine1B receptor is localized predominantly on axon terminals.
Neuroscience.
1994; 58(1): 167–82. PubMed Abstract
| Publisher Full Text
- 28.
Ghavami A, Stark KL, Jareb M, et al.:
Differential addressing of 5-HT1A and 5-HT1B receptors in epithelial cells and neurons.
J Cell Sci.
1999; 112(Pt 6): 967–76. PubMed Abstract
- 29.
Riad M, Garcia S, Watkins KC, et al.:
Somatodendritic localization of 5-HT1A and preterminal axonal localization of 5-HT1B serotonin receptors in adult rat brain.
J Comp Neurol.
2000; 417(2): 181–94. PubMed Abstract
| Publisher Full Text
- 30.
Beck SG, Choi KC, List TJ:
Comparison of 5-hydroxytryptamine1A-mediated hyperpolarization in CA1 and CA3 hippocampal pyramidal cells.
J Pharmacol Exp Ther.
1992; 263(1): 350–9. PubMed Abstract
- 31.
Knobelman DA, Kung HF, Lucki I:
Regulation of extracellular concentrations of 5-hydroxytryptamine (5-HT) in mouse striatum by 5-HT1A and 5-HT1B receptors.
J Pharmacol Exp Ther.
2000; 292(3): 1111–7. PubMed Abstract
- 32.
Mizutani H, Hori T, Takahashi T:
5-HT1B receptor-mediated presynaptic inhibition at the calyx of Held of immature rats.
Eur J Neurosci.
2006; 24(7): 1946–54. PubMed Abstract
| Publisher Full Text
- 33.
Hagan CE, McDevitt RA, Liu Y, et al.:
5-HT1B autoreceptor regulation of serotonin transporter activity in synaptosomes.
Synapse.
2012; 66(12): 1024–34. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 34.
Montanez S, Munn JL, Owens WA, et al.:
5-HT1B receptor modulation of the serotonin transporter in vivo: studies using KO mice.
Neurochem Int.
2014; 73: 127–31. PubMed Abstract
| Publisher Full Text
| Free Full Text
| Faculty Opinions Recommendation
- 35.
Clark MS, McDevitt RA, Neumaier JF:
Quantitative mapping of tryptophan hydroxylase-2, 5-HT1A, 5-HT1B, and serotonin transporter expression across the anteroposterior axis of the rat dorsal and median raphe nuclei.
J Comp Neurol.
2006; 498(5): 611–23. PubMed Abstract
| Publisher Full Text
- 36.
Maroteaux L, Saudou F, Amlaiky N, et al.:
Mouse 5HT1B serotonin receptor: cloning, functional expression, and localization in motor control centers.
Proc Natl Acad Sci U S A.
1992; 89(7): 3020–4. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 37.
Pompeiano M, Palacios JM, Mengod G:
Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding.
J Neurosci.
1992; 12(2): 440–53. PubMed Abstract
- 38.
Donaldson ZR, Hen R:
From psychiatric disorders to animal models: a bidirectional and dimensional approach.
Biol Psychiatry.
2015; 77(1): 15–21. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 39.
Savitz J, Lucki I, Drevets WC:
5-HT1A receptor function in major depressive disorder.
Prog Neurobiol.
2009; 88(1): 17–31. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 40.
Parsey RV, Ogden RT, Miller JM, et al.:
Higher serotonin 1A binding in a second major depression cohort: modeling and reference region considerations.
Biol Psychiatry.
2010; 68(2): 170–8. PubMed Abstract
| Publisher Full Text
| Free Full Text
| Faculty Opinions Recommendation
- 41.
Kaufman J, Sullivan GM, Yang J, et al.:
Quantification of the Serotonin 1A Receptor Using PET: Identification of a Potential Biomarker of Major Depression in Males.
Neuropsychopharmacology.
2015; 40(7): 1692–9. PubMed Abstract
| Publisher Full Text
| Free Full Text
| Faculty Opinions Recommendation
- 42.
Stockmeier CA, Shapiro LA, Dilley GE, et al.:
Increase in serotonin-1A autoreceptors in the midbrain of suicide victims with major depression-postmortem evidence for decreased serotonin activity.
J Neurosci.
1998; 18(18): 7394–401. PubMed Abstract
- 43.
Donaldson ZR, Le Francois B, Santos TL, et al.:
The functional serotonin 1a receptor promoter polymorphism, rs6295, is associated with psychiatric illness and differences in transcription.
Transl Psychiatry.
2016; 6: e746. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 44.
Albert PR, Lemonde S:
5-HT1A receptors, gene repression, and depression: guilt by association.
Neuroscientist.
2004; 10(6): 575–93. PubMed Abstract
| Publisher Full Text
- 45.
Albert PR:
Transcriptional regulation of the 5-HT1A receptor: implications for mental illness.
Philos Trans R Soc Lond B Biol Sci.
2012; 367(1601): 2402–15. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 46.
Strobel A, Gutknecht L, Rothe C, et al.:
Allelic variation in 5-HT1A receptor expression is associated with anxiety- and depression-related personality traits.
J Neural Transm (Vienna).
2003; 110(12): 1445–53. PubMed Abstract
| Publisher Full Text
- 47.
Lemonde S, Turecki G, Bakish D, et al.:
Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide.
J Neurosci.
2003; 23(25): 8788–99. PubMed Abstract
| Faculty Opinions Recommendation
- 48.
Parsey RV, Olvet DM, Oquendo MA, et al.:
Higher 5-HT1A receptor binding potential during a major depressive episode predicts poor treatment response: preliminary data from a naturalistic study.
Neuropsychopharmacology.
2006; 31(8): 1745–9. PubMed Abstract
| Publisher Full Text
- 49.
Robinson DS, Rickels K, Feighner J, et al.:
Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression.
J Clin Psychopharmacol.
1990; 10(3 Suppl): 67S–76S. PubMed Abstract
- 50.
Lucki I:
Behavioral studies of serotonin receptor agonists as antidepressant drugs.
J Clin Psychiatry.
1991; 52 Suppl: 24–31. PubMed Abstract
- 51.
Kennett GA, Dourish CT, Curzon G:
Antidepressant-like action of 5-HT1A agonists and conventional antidepressants in an animal model of depression.
Eur J Pharmacol.
1987; 134(3): 265–74. PubMed Abstract
| Publisher Full Text
- 52.
Detke MJ, Rickels M, Lucki I:
Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants.
Psychopharmacology (Berl).
1995; 121(1): 66–72. PubMed Abstract
| Publisher Full Text
- 53.
López-Rubalcava C, Lucki I:
Strain differences in the behavioral effects of antidepressant drugs in the rat forced swimming test.
Neuropsychopharmacology.
2000; 22(2): 191–9. PubMed Abstract
| Publisher Full Text
- 54.
Detke MJ, Wieland S, Lucki I:
Blockade of the antidepressant-like effects of 8-OH-DPAT, buspirone and desipramine in the rat forced swim test by 5HT1A receptor antagonists.
Psychopharmacology (Berl).
1995; 119(1): 47–54. PubMed Abstract
| Publisher Full Text
- 55.
Blier P, de Montigny C:
Current advances and trends in the treatment of depression.
Trends Pharmacol Sci.
1994; 15(7): 220–6. PubMed Abstract
| Publisher Full Text
- 56.
Albert PR, Lembo P, Storring JM, et al.:
The 5-HT1A receptor: signaling, desensitization, and gene transcription.
Neuropsychopharmacology.
1996; 14(1): 19–25. PubMed Abstract
| Publisher Full Text
- 57.
Blier P, Ward NM:
Is there a role for 5-HT1A agonists in the treatment of depression?
Biol Psychiatry.
2003; 53(3): 193–203. PubMed Abstract
| Publisher Full Text
- 58.
Blier P, Piñeyro G, el Mansari M, et al.:
Role of somatodendritic 5-HT autoreceptors in modulating 5-HT neurotransmission.
Ann N Y Acad Sci.
1998; 861: 204–16. PubMed Abstract
| Publisher Full Text
- 59.
Tome MB, Isaac MT, Harte R, et al.:
Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency.
Int Clin Psychopharmacol.
1997; 12(2): 81–9. PubMed Abstract
- 60.
Artigas F, Celada P, Laruelle M, et al.:
How does pindolol improve antidepressant action?
Trends Pharmacol Sci.
2001; 22(5): 224–8. PubMed Abstract
| Publisher Full Text
- 61.
Sahli ZT, Banerjee P, Tarazi FI:
The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder.
Expert Opin Drug Discov.
2016; 11(5): 515–23. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 62.
Artigas F, Romero L, de Montigny C, et al.:
Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists.
Trends Neurosci.
1996; 19(9): 378–83. PubMed Abstract
| Publisher Full Text
- 63.
Newman-Tancredi A, Martel JC, Assié MB, et al.:
Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist.
Br J Pharmacol.
2009; 156(2): 338–53. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 64.
Ramboz S, Oosting R, Amara DA, et al.:
Serotonin receptor 1A knockout: an animal model of anxiety-related disorder.
Proc Natl Acad Sci U S A.
1998; 95(24): 14476–81. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 65.
Heisler LK, Chu HM, Brennan TJ, et al.:
Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant mice.
Proc Natl Acad Sci U S A.
1998; 95(25): 15049–54. PubMed Abstract
| Free Full Text
- 66.
Richardson-Jones JW, Craige CP, Nguyen TH, et al.:
Serotonin-1A autoreceptors are necessary and sufficient for the normal formation of circuits underlying innate anxiety.
J Neurosci.
2011; 31(16): 6008–18. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 67.
Santarelli L, Saxe M, Gross C, et al.:
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants.
Science.
2003; 301(5634): 805–9. PubMed Abstract
| Publisher Full Text
| Faculty Opinions Recommendation
- 68.
Richardson-Jones JW, Craige CP, Guiard BP, et al.:
5-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants.
Neuron.
2010; 65(1): 40–52. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 69.
Samuels BA, Anacker C, Hu A, et al.:
5-HT1A receptors on mature dentate gyrus granule cells are critical for the antidepressant response.
Nat Neurosci.
2015; 18(11): 1606–16. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 70.
Fava M, Rankin MA, Wright EC, et al.:
Anxiety disorders in major depression.
Compr Psychiatry.
2000; 41(2): 97–102. PubMed Abstract
| Publisher Full Text
- 71.
de Vry J:
5-HT1A receptor agonists: recent developments and controversial issues.
Psychopharmacology (Berl).
1995; 121(1): 1–26. PubMed Abstract
| Publisher Full Text
- 72.
Parks CL, Robinson PS, Sibille E, et al.:
Increased anxiety of mice lacking the serotonin1A receptor.
Proc Natl Acad Sci U S A.
1998; 95(18): 10734–9. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 73.
Gross C, Zhuang X, Stark K, et al.:
Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult.
Nature.
2002; 416(6879): 396–400. PubMed Abstract
| Publisher Full Text
| Faculty Opinions Recommendation
- 74.
Lo Iacono L, Gross C:
α-Ca2+/calmodulin-dependent protein kinase II contributes to the developmental programming of anxiety in serotonin receptor 1A knock-out mice.
J Neurosci.
2008; 28(24): 6250–7. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 75.
Vinkers CH, Oosting RS, van Bogaert, et al.:
Early-life blockade of 5-HT1A receptors alters adult anxiety behavior and benzodiazepine sensitivity.
Biol Psychiatry.
2010; 67(4): 309–16. PubMed Abstract
| Publisher Full Text
- 76.
Garcia-Garcia AL, Meng Q, Richardson-Jones J, et al.:
Disruption of 5-HT1A function in adolescence but not early adulthood leads to sustained increases of anxiety.
Neuroscience.
2016; 321: 210–21. PubMed Abstract
| Publisher Full Text
| Free Full Text
| Faculty Opinions Recommendation
- 77.
Donaldson ZR, Piel DA, Santos TL, et al.:
Developmental effects of serotonin 1A autoreceptors on anxiety and social behavior.
Neuropsychopharmacology.
2014; 39(2): 291–302. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 78.
Sullivan GM, Ogden RT, Huang Y, et al.:
Higher in vivo serotonin-1a binding in posttraumatic stress disorder: a PET study with [11C]WAY-100635.
Depress Anxiety.
2013; 30(3): 197–206. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 79.
Sullivan GM, Ogden RT, Oquendo MA, et al.:
Positron emission tomography quantification of serotonin-1A receptor binding in medication-free bipolar depression.
Biol Psychiatry.
2009; 66(3): 223–30. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 80.
Hjorth S, Suchowski CS, Galloway MP:
Evidence for 5-HT autoreceptor-mediated, nerve impulse-independent, control of 5-HT synthesis in the rat brain.
Synapse.
1995; 19(3): 170–6. PubMed Abstract
| Publisher Full Text
- 81.
Trillat AC, Malagié I, Scearce K, et al.:
Regulation of serotonin release in the frontal cortex and ventral hippocampus of homozygous mice lacking 5-HT1B receptors: in vivo microdialysis studies.
J Neurochem.
1997; 69(5): 2019–25. PubMed Abstract
| Publisher Full Text
- 82.
Murrough JW, Henry S, Hu J, et al.:
Reduced ventral striatal/ventral pallidal serotonin1B receptor binding potential in major depressive disorder.
Psychopharmacology (Berl).
2011; 213(2–3): 547–53. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 83.
Whale R, Clifford EM, Bhagwagar Z, et al.:
Decreased sensitivity of 5-HT1D receptors in melancholic depression.
Br J Psychiatry.
2001; 178(5): 454–7. PubMed Abstract
| Publisher Full Text
- 84.
Cleare AJ, Murray RM, Sherwood RA, et al.:
Abnormal 5-HT1D receptor function in major depression: a neuropharmacological challenge study using sumatriptan.
Psychol Med.
1998; 28(2): 295–300. PubMed Abstract
- 85.
Stern L, Zohar J, Cohen R, et al.:
Treatment of severe, drug resistant obsessive compulsive disorder with the 5HT1D agonist sumatriptan.
Eur Neuropsychopharmacol.
1998; 8(4): 325–8. PubMed Abstract
| Publisher Full Text
- 86.
Tatarczynska E, Antkiewicz-Michaluk L, Klodzinska A, et al.:
Antidepressant-like effect of the selective 5-HT1B receptor agonist CP 94253: a possible mechanism of action.
Eur J Pharmacol.
2005; 516(1): 46–50. PubMed Abstract
| Publisher Full Text
- 87.
Miranda H, Ortiz G, Figueroa S, et al.:
Depression scores following migraine treatment in patients attending a specialized center for headache and neurology.
Headache.
2001; 41(7): 680–4. PubMed Abstract
| Publisher Full Text
- 88.
Redrobe JP, Bourin M:
Evidence of the activity of lithium on 5-HT1B receptors in the mouse forced swimming test: comparison with carbamazepine and sodium valproate.
Psychopharmacology (Berl ).
1999; 141(4): 370–7. PubMed Abstract
| Publisher Full Text
- 89.
O'Neill MF, Conway MW:
Role of 5-HT1A and 5-HT1B receptors in the mediation of behavior in the forced swim test in mice.
Neuropsychopharmacology.
2001; 24(4): 391–8. PubMed Abstract
| Publisher Full Text
- 90.
Knobelman DA, Hen R, Lucki I:
Genetic regulation of extracellular serotonin by 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) autoreceptors in different brain regions of the mouse.
J Pharmacol Exp Ther.
2001; 298(3): 1083–91. PubMed Abstract
- 91.
Malagié I, Trillat AC, Bourin M, et al.:
5-HT1B Autoreceptors limit the effects of selective serotonin re-uptake inhibitors in mouse hippocampus and frontal cortex.
J Neurochem.
2001; 76(3): 865–71. PubMed Abstract
| Publisher Full Text
- 92.
Jones MD, Lucki I:
Sex differences in the regulation of serotonergic transmission and behavior in 5-HT receptor knockout mice.
Neuropsychopharmacology.
2005; 30(6): 1039–47. PubMed Abstract
| Publisher Full Text
- 93.
Bechtholt AJ, Smith K, Gaughan S, et al.:
Sucrose intake and fasting glucose levels in 5-HT1A and 5-HT1B receptor mutant mice.
Physiol Behav.
2008; 93(4–5): 659–65. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 94.
Mayorga AJ, Dalvi A, Page ME, et al.:
Antidepressant-like behavioral effects in 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) receptor mutant mice.
J Pharmacol Exp Ther.
2001; 298(3): 1101–7. PubMed Abstract
- 95.
Sari Y:
Serotonin1B receptors: from protein to physiological function and behavior.
Neurosci Biobehav Rev.
2004; 28(6): 565–82. PubMed Abstract
| Publisher Full Text
- 96.
Nautiyal KM, Tanaka KF, Barr MM, et al.:
Distinct Circuits Underlie the Effects of 5-HT1B Receptors on Aggression and Impulsivity.
Neuron.
2015; 86(3): 813–26. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 97.
Nautiyal KM, Tritschler L, Ahmari SE, et al.:
A Lack of Serotonin 1B Autoreceptors Results in Decreased Anxiety and Depression-Related Behaviors.
Neuropsychopharmacology.
2016; 41(12): 2941–50. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 98.
Neumaier JF, Petty F, Kramer GL, et al.:
Learned helplessness increases 5-hydroxytryptamine1B receptor mRNA levels in the rat dorsal raphe nucleus.
Biol Psychiatry.
1997; 41(6): 668–74. PubMed Abstract
| Publisher Full Text
- 99.
Neumaier JF, Edwards E, Plotsky PM:
5-HT1B mrna regulation in two animal models of altered stress reactivity.
Biol Psychiatry.
2002; 51(11): 902–8. PubMed Abstract
| Publisher Full Text
- 100.
Clark MS, Sexton TJ, McClain M, et al.:
Overexpression of 5-HT1B receptor in dorsal raphe nucleus using Herpes Simplex Virus gene transfer increases anxiety behavior after inescapable stress.
J Neurosci.
2002; 22(11): 4550–62. PubMed Abstract
- 101.
Neumaier JF, Root DC, Hamblin MW:
Chronic fluoxetine reduces serotonin transporter mRNA and 5-HT1B mRNA in a sequential manner in the rat dorsal raphe nucleus.
Neuropsychopharmacology.
1996; 15(5): 515–22. PubMed Abstract
| Publisher Full Text
- 102.
Anthony JP, Sexton TJ, Neumaier JF:
Antidepressant-induced regulation of 5-HT1b mRNA in rat dorsal raphe nucleus reverses rapidly after drug discontinuation.
J Neurosci Res.
2000; 61(1): 82–7. PubMed Abstract
| Publisher Full Text
- 103.
Davidson C, Stamford JA:
Effect of chronic paroxetine treatment on 5-HT1B and 5-HT1D autoreceptors in rat dorsal raphe nucleus.
Neurochem Int.
2000; 36(2): 91–6. PubMed Abstract
| Publisher Full Text
- 104.
Tiger M, Rück C, Forsberg A, et al.:
Reduced 5-HT1B receptor binding in the dorsal brain stem after cognitive behavioural therapy of major depressive disorder.
Psychiatry Res.
2014; 223(2): 164–70. PubMed Abstract
| Publisher Full Text
| Faculty Opinions Recommendation
- 105.
Chenu F, David DJ, Leroux-Nicollet I, et al.:
Serotonin1B heteroreceptor activation induces an antidepressant-like effect in mice with an alteration of the serotonergic system.
J Psychiatry Neurosci.
2008; 33(6): 541–50. PubMed Abstract
| Free Full Text
- 106.
Svenningsson P, Chergui K, Rachleff I, et al.:
Alterations in 5-HT1B receptor function by p11 in depression-like states.
Science.
2006; 311(5757): 77–80. PubMed Abstract
| Publisher Full Text
| Faculty Opinions Recommendation
- 107.
Alexander B, Warner-Schmidt J, Eriksson T, et al.:
Reversal of depressed behaviors in mice by p11 gene therapy in the nucleus accumbens.
Sci Transl Med.
2010; 2(54): 54ra76. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 108.
Lim BK, Huang KW, Grueter BA, et al.:
Anhedonia requires MC4R-mediated synaptic adaptations in nucleus accumbens.
Nature.
2012; 487(7406): 183–9. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 109.
Brown AS, Gershon S:
Dopamine and depression.
J Neural Transm Gen Sect.
1993; 91(2–3): 75–109. PubMed Abstract
| Publisher Full Text
- 110.
D'Aquila PS, Collu M, Gessa GL, et al.:
The role of dopamine in the mechanism of action of antidepressant drugs.
Eur J Pharmacol.
2000; 405(1–3): 365–73. PubMed Abstract
| Publisher Full Text
- 111.
Nestler EJ, Carlezon WA Jr:
The mesolimbic dopamine reward circuit in depression.
Biol Psychiatry.
2006; 59(12): 1151–9. PubMed Abstract
| Publisher Full Text
- 112.
Heshmati M, Russo SJ:
Anhedonia and the brain reward circuitry in depression.
Curr Behav Neurosci Rep.
2015; 2(3): 146–53. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 113.
Barot SK, Ferguson SM, Neumaier JF:
5-HT1B receptors in nucleus accumbens efferents enhance both rewarding and aversive effects of cocaine.
Eur J Neurosci.
2007; 25(10): 3125–31. PubMed Abstract
| Publisher Full Text
- 114.
Dolen G, Darvishzadeh A, Huang KW, et al.:
Social reward requires coordinated activity of nucleus accumbens oxytocin and serotonin.
Nature.
2013; 501(7466): 179–84. PubMed Abstract
| Publisher Full Text
| Free Full Text
| Faculty Opinions Recommendation
- 115.
Zouk H, McGirr A, Lebel V, et al.:
The effect of genetic variation of the serotonin 1B receptor gene on impulsive aggressive behavior and suicide.
Am J Med Genet B Neuropsychiatr Genet.
2007; 144B(8): 996–1002. PubMed Abstract
| Publisher Full Text
- 116.
Potenza MN, Walderhaug E, Henry S, et al.:
Serotonin 1B receptor imaging in pathological gambling.
World J Biol Psychiatry.
2013; 14(2): 139–45. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 117.
O'Dell LE, Parsons LH:
Serotonin1B receptors in the ventral tegmental area modulate cocaine-induced increases in nucleus accumbens dopamine levels.
J Pharmacol Exp Ther.
2004; 311(2): 711–9. PubMed Abstract
| Publisher Full Text
- 118.
Contini V, Bertuzzi GP, Polina ER, et al.:
A haplotype analysis is consistent with the role of functional HTR1B variants in alcohol dependence.
Drug Alcohol Depend.
2012; 122(1–2): 100–4. PubMed Abstract
| Publisher Full Text
- 119.
Proudnikov D, LaForge KS, Hofflich H, et al.:
Association analysis of polymorphisms in serotonin 1B receptor (HTR1B) gene with heroin addiction: a comparison of molecular and statistically estimated haplotypes.
Pharmacogenet Genomics.
2006; 16(1): 25–36. PubMed Abstract
| Publisher Full Text
- 120.
Cao J, LaRocque E, Li D:
Associations of the 5-hydroxytryptamine (serotonin) receptor 1B gene (HTR1B) with alcohol, cocaine, and heroin abuse.
Am J Med Genet B Neuropsychiatr Genet.
2013; 162B(2): 169–76. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 121.
Petry NM, Stinson FS, Grant BF:
Comorbidity of DSM-IV pathological gambling and other psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions.
J Clin Psychiatry.
2005; 66(5): 564–74. PubMed Abstract
| Publisher Full Text
- 122.
Matuskey D, Bhagwagar Z, Planeta B, et al.:
Reductions in brain 5-HT1B receptor availability in primarily cocaine-dependent humans.
Biol Psychiatry.
2014; 76(10): 816–22. PubMed Abstract
| Publisher Full Text
| Free Full Text
| Faculty Opinions Recommendation
- 123.
Rocha BA, Scearce-Levie K, Lucas JJ, et al.:
Increased vulnerability to cocaine in mice lacking the serotonin-1B receptor.
Nature.
1998; 393(6681): 175–8. PubMed Abstract
| Publisher Full Text
- 124.
Pentkowski NS, Acosta JI, Browning JR, et al.:
Stimulation of 5-HT1B receptors enhances cocaine reinforcement yet reduces cocaine-seeking behavior.
Addict Biol.
2009; 14(4): 419–30. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 125.
Neumaier JF, Vincow ES, Arvanitogiannis A, et al.:
Elevated expression of 5-HT1B receptors in nucleus accumbens efferents sensitizes animals to cocaine.
J Neurosci.
2002; 22(24): 10856–63. PubMed Abstract
- 126.
Pentkowski NS, Cheung TH, Toy WA, et al.:
Protracted withdrawal from cocaine self-administration flips the switch on 5-HT1B receptor modulation of cocaine abuse-related behaviors.
Biol Psychiatry.
2012; 72(5): 396–404. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 127.
Conner TS, Jensen KP, Tennen H, et al.:
Functional polymorphisms in the serotonin 1B receptor gene (HTR1B) predict self-reported anger and hostility among young men.
Am J Med Genet B Neuropsychiatr Genet.
2010; 153B(1): 67–78. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 128.
Pattij T, Broersen LM, van der Linde J, et al.:
Operant learning and differential-reinforcement-of-low-rate 36-s responding in 5-HT1A and 5-HT1B receptor knockout mice.
Behav Brain Res.
2003; 141(2): 137–45. PubMed Abstract
| Publisher Full Text
- 129.
Saudou F, Amara DA, Dierich A, et al.:
Enhanced aggressive behavior in mice lacking 5-HT1B receptor.
Science.
1994; 265(5180): 1875–8. PubMed Abstract
| Publisher Full Text
- 130.
Olivier B, Mos J, van Oorschot R, et al.:
Serotonin receptors and animal models of aggressive behavior.
Pharmacopsychiatry.
1995; 28(Suppl 2): 80–90. PubMed Abstract
| Publisher Full Text
- 131.
de Boer SF, Koolhaas JM:
5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis.
Eur J Pharmacol.
2005; 526(1–3): 125–39. PubMed Abstract
| Publisher Full Text
- 132.
Rush AJ, Trivedi MH, Wisniewski SR, et al.:
Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.
Am J Psychiatry.
2006; 163(11): 1905–17. PubMed Abstract
| Publisher Full Text
- 133.
Quesseveur G, Reperant C, David DJ, et al.:
5-HT2A receptor inactivation potentiates the acute antidepressant-like activity of escitalopram: involvement of the noradrenergic system.
Exp Brain Res.
2013; 226(2): 285–95. PubMed Abstract
| Publisher Full Text
- 134.
Patel JG, Bartoszyk GD, Edwards E, et al.:
The highly selective 5-hydroxytryptamine (5-HT)2A receptor antagonist, EMD 281014, significantly increases swimming and decreases immobility in male congenital learned helpless rats in the forced swim test.
Synapse.
2004; 52(1): 73–5. PubMed Abstract
| Publisher Full Text
- 135.
Weisstaub NV, Zhou M, Lira A, et al.:
Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice.
Science.
2006; 313(5786): 536–40. PubMed Abstract
| Publisher Full Text
| Faculty Opinions Recommendation
- 136.
Meltzer HY:
The role of serotonin in antipsychotic drug action.
Neuropsychopharmacology.
1999; 21(2 Suppl): 106S–115S. PubMed Abstract
| Publisher Full Text
- 137.
Halberstadt AL, Geyer MA:
Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens.
Neuropharmacology.
2011; 61(3): 364–81. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 138.
Diaz SL, Doly S, Narboux-Neme N, et al.:
5-HT2B receptors are required for serotonin-selective antidepressant actions.
Mol Psychiatry.
2012; 17(2): 154–63. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 139.
Diaz SL, Narboux-Neme N, Boutourlinsky K, et al.:
Mice lacking the serotonin 5-HT2B receptor as an animal model of resistance to selective serotonin reuptake inhibitors antidepressants.
Eur Neuropsychopharmacol.
2016; 26(2): 265–79. PubMed Abstract
| Publisher Full Text
| Faculty Opinions Recommendation
- 140.
Bevilacqua L, Doly S, Kaprio J, et al.:
A population-specific HTR2B stop codon predisposes to severe impulsivity.
Nature.
2010; 468(7327): 1061–6. PubMed Abstract
| Publisher Full Text
| Free Full Text
| Faculty Opinions Recommendation
- 141.
Cryan JF, Lucki I:
Antidepressant-like behavioral effects mediated by 5-hydroxytryptamine2C receptors.
J Pharmacol Exp Ther.
2000; 295(3): 1120–6. PubMed Abstract
- 142.
Opal MD, Klenotich SC, Morais M, et al.:
Serotonin 2C receptor antagonists induce fast-onset antidepressant effects.
Mol Psychiatry.
2014; 19(10): 1106–14. PubMed Abstract
| Publisher Full Text
| Faculty Opinions Recommendation
- 143.
Heisler LK, Zhou L, Bajwa P, et al.:
Serotonin 5-HT2C receptors regulate anxiety-like behavior.
Genes Brain Behav.
2007; 6(5): 491–6. PubMed Abstract
| Publisher Full Text
- 144.
Higgins GA, Silenieks LB, Altherr EB, et al.:
Lorcaserin and CP-809101 reduce motor impulsivity and reinstatement of food seeking behavior in male rats: Implications for understanding the anti-obesity property of 5-HT2C receptor agonists.
Psychopharmacology (Berl).
2016; 233(14): 2841–56. PubMed Abstract
| Publisher Full Text
- 145.
Griebel G, Perrault G, Sanger DJ:
A comparative study of the effects of selective and non-selective 5-HT2 receptor subtype antagonists in rat and mouse models of anxiety.
Neuropharmacology.
1997; 36(6): 793–802. PubMed Abstract
| Publisher Full Text
- 146.
Ramamoorthy R, Radhakrishnan M, Borah M:
Antidepressant-like effects of serotonin type-3 antagonist, ondansetron: an investigation in behaviour-based rodent models.
Behav Pharmacol.
2008; 19(1): 29–40. PubMed Abstract
| Publisher Full Text
- 147.
Kondo M, Nakamura Y, Ishida Y, et al.:
The 5-HT3 receptor is essential for exercise-induced hippocampal neurogenesis and antidepressant effects.
Mol Psychiatry.
2015; 20(11): 1428–37. PubMed Abstract
| Publisher Full Text
- 148.
Bhatnagar S, Nowak N, Babich L, et al.:
Deletion of the 5-HT3 receptor differentially affects behavior of males and females in the Porsolt forced swim and defensive withdrawal tests.
Behav Brain Res.
2004; 153(2): 527–35. PubMed Abstract
| Publisher Full Text
- 149.
Costall B, Naylor RJ:
Anxiolytic potential of 5-HT3 receptor antagonists.
Pharmacol Toxicol.
1992; 70(3): 157–62. PubMed Abstract
| Publisher Full Text
- 150.
Lucas G, Rymar VV, Du J, et al.:
Serotonin4 (5-HT4) receptor agonists are putative antidepressants with a rapid onset of action.
Neuron.
2007; 55(5): 712–25. PubMed Abstract
| Publisher Full Text
| Faculty Opinions Recommendation
- 151.
Mendez-David I, David DJ, Darcet F, et al.:
Rapid anxiolytic effects of a 5-HT4 receptor agonist are mediated by a neurogenesis-independent mechanism.
Neuropsychopharmacology.
2014; 39(6): 1366–78. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 152.
Compan V, Zhou M, Grailhe R, et al.:
Attenuated response to stress and novelty and hypersensitivity to seizures in 5-HT4 receptor knock-out mice.
J Neurosci.
2004; 24(2): 412–9. PubMed Abstract
| Publisher Full Text
- 153.
Jean A, Conductier G, Manrique C, et al.:
Anorexia induced by activation of serotonin 5-HT4 receptors is mediated by increases in CART in the nucleus accumbens.
Proc Natl Acad Sci U S A.
2007; 104(41): 16335–40. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 154.
Waeber C, Grailhe R, Yu XJ, et al.:
Putative 5-Ht5 receptors: localization in the mouse CNS and lack of effect in the inhibition of dural protein extravasation.
Ann N Y Acad Sci.
1998; 861: 85–90. PubMed Abstract
| Publisher Full Text
- 155.
Svenningsson P, Tzavara ET, Qi H, et al.:
Biochemical and behavioral evidence for antidepressant-like effects of 5-HT6 receptor stimulation.
J Neurosci.
2007; 27(15): 4201–9. PubMed Abstract
| Publisher Full Text
- 156.
Carr GV, Schechter LE, Lucki I:
Antidepressant and anxiolytic effects of selective 5-HT6 receptor agonists in rats.
Psychopharmacology (Berl).
2011; 213(2–3): 499–507. PubMed Abstract
| Publisher Full Text
| Free Full Text
- 157.
Mitchell ES, Neumaier JF:
5-HT6 receptors: a novel target for cognitive enhancement.
Pharmacol Ther.
2005; 108(3): 320–33. PubMed Abstract
| Publisher Full Text
- 158.
Hamon M, Doucet E, Lefèvre K, et al.:
Antibodies and antisense oligonucleotide for probing the distribution and putative functions of central 5-HT6 receptors.
Neuropsychopharmacology.
1999; 21(2 Suppl): 68S–76S. PubMed Abstract
| Publisher Full Text
- 159.
Guscott M, Bristow LJ, Hadingham K, et al.:
Genetic knockout and pharmacological blockade studies of the 5-HT7 receptor suggest therapeutic potential in depression.
Neuropharmacology.
2005; 48(4): 492–502. PubMed Abstract
| Publisher Full Text
| Faculty Opinions Recommendation
- 160.
Ballaz SJ, Akil H, Watson SJ:
The 5-HT7 receptor: role in novel object discrimination and relation to novelty-seeking behavior.
Neuroscience.
2007; 149(1): 192–202. PubMed Abstract
| Publisher Full Text
Comments on this article Comments (0)